

AmerisourceBergen

March 2, 2022

Dear valued customer,

Attached is a letter announcing that we, along with our pharmaceutical distribution peers, have agreed to a nationwide settlement that resolves most of the opioid-related lawsuits filed by state and local government entities across the country.

As part of the settlement agreement, we will be required to make some changes to our Controlled Substance Monitoring Program (CSMP). These changes will ensure consistency across the distribution industry and will impact the manner in which we conduct diligence reviews, data collection and analysis, monthly limits on controlled substance ordering, and suspicious order reporting. We are preparing for the changes to go into effect in July 2022.

These **new requirements will apply to all customers who are registered with the DEA as a Retail Pharmacy, including independents, chains and mail order pharmacies.** The new requirements will not apply to closed-door retail pharmacies servicing long-term care and hospice patient communities, hospital inpatient pharmacies, physician practices, clinics, distributors or researchers.

Over the next several months, we will work closely with you to prepare for the new requirements and ensure that all of your questions and concerns are addressed. We have created an Injunctive Relief webpage (<https://amerisourcebergen.com/injunctiverelief>) where we will provide up-to-date information and support materials.

AmerisourceBergen is committed to ensuring patients have access to needed medications while doing our part to combat the misuse, abuse and potential diversion of controlled substances, and we will work in partnership with you to help ensure continuity of care for your patients. We appreciate your support and partnership.

With questions, please check out our webpage of resources or contact your AB representative.

Sincerely,

AmerisourceBergen